Larvol Delta - Beacon-Therapeutics-Announces-Positive-Phase-2-Interim-6Month-Data-from-DAWN-Trial-of-Laruzova-in-Patients-with-Xlinked-Retinitis-Pigmentosa-XLRP-at-ARVO-2025

laruparetigene zovaparvovec (AGTC-501) - AGTC

https://www.globenewswire.com/news-release/2025/05/06/3075349/30580/en/Beacon-Therapeutics-Announces-Positive-Phase-2-Interim-6-Month-Data-from-DAWN-Trial-of-Laru-zova-in-Patients-with-X-linked-Retinitis-Pigmentosa-XLRP-at-ARVO-2025.html

May 6, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next